Structure Therapeutics (GPCR) Cash from Investing Activities (2022 - 2026)

Structure Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$496.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 1560.19% year-over-year to -$496.9 million; the TTM figure through Mar 2026 stood at -$441.2 million (down 35.21% YoY), while the FY2025 annual figure was $89.8 million, up 125.02% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$496.9 million, down from $56.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $56.1 million in Q4 2025, with the low at -$496.9 million in Q1 2026.
• The 5-year median for Cash from Investing Activities is -$16.7 million (2022), against an average of -$64.5 million.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities slumped 1847.84% in 2023, then jumped 2300.07% in 2025.
• Structure Therapeutics' Cash from Investing Activities stood at $10.3 million in 2022, then plunged by 1847.84% to -$180.7 million in 2023, then surged by 118.39% to $33.2 million in 2024, then surged by 68.93% to $56.1 million in 2025, then tumbled by 985.19% to -$496.9 million in 2026.
• Business Quant data shows GPCR's Cash from Investing Activities at -$496.9 million in Q1 2026, $56.1 million in Q4 2025, and -$49.3 million in Q3 2025.